Ketone compounds and compositions for cholesterol management and related uses
The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
1. A method for treating diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, or insulin resistance, relating to diabetes, comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound selected from a group consisting of:
t-butyl-1-[9-[1-(tert-butyoxycarbonyl)cyclopropyl]-5-oxononyl]-1-cyclopropanecarboxylate;
11-(1-carboxycyclopropyl)-2,2-dimethyl-7-oxoundecanoic acid;
1-[9-(1-carboxycyclopropyl)-5-oxononyl]-1-cyclopropanecarboxylic acid;
11-(1-carboxycyclobutyl)-2,2-dimethyl-7-oxoundecanoic acid;
1-[9-(1-carboxycyclobutyl)-5-oxononyl]-1-cyclobutanecarboxylic acid;
1-[9-(1-carboxycyclopentyl)-5-oxononyl]-1-cyclopentylcarboxylic acid;
13-(1-carboxycyclopropyl)-2,2-dimethyl-8-oxotridecanoic acid;
1-[11-(1-carboxycyclopropyl)-6-oxoundecyl]-1-cyclopropanecarboxylic acid; and
1-[11-(1-carboxycyclopentyl)-6-oxoundecyl]-1-cyclopentanecarboxylic acid;
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the compound is selected from a group consisting of:
t-butyl-1-[9-[1-(tert-butyoxycarbonyl)cyclopropyl]-5-oxononyl]-1-cyclopropanecarboxylate;
1-[9-(1-carboxycyclopropyl)-5-oxononyl]-1-cyclopropanecarboxylic acid;
1-[9-(1-carboxycyclobutyl)-5-oxononyl]-1-cyclobutanecarboxylic acid;
1-[9-(1-carboxycyclopentyl)-5-oxononyl]-1-cyclopentylcarboxylic acid;
1-[11-(1-carboxycyclopropyl)-6-oxoundecyl]-1-cyclopropanecarboxylic acid; and
1-[11-(1-carboxycyclopentyl)-6-oxoundecyl]-1-cyclopentanecarboxylic acid;
or a pharmaceutically acceptable salt thereof.
3. The method of claim 2 , wherein the compound is t-butyl-1-[9-[1-(tert-butyoxycarbonyl)cyclopropyl]-5-oxononyl]-1-cyclopropanecarboxylate, or a pharmaceutically acceptable salt thereof.
4. The method of claim 2 , wherein the compound is 1-[9-(1-carboxycyclopropyl)-5-oxononyl]-1-cyclopropanecarboxylic acid, or a pharmaceutically acceptable salt thereof.
5. The method of claim 2 , wherein the compound is 1-[9-(1-carboxycyclobutyl)-5-oxononyl]-1-cyclobutanecarboxylic acid, or a pharmaceutically acceptable salt thereof.
6. The method of claim 2 , wherein the compound is 1-[9-(1-carboxycyclopentyl)-5-oxononyl]-1-cyclopentylcarboxylic acid, or a pharmaceutically acceptable salt thereof.
7. The method of claim 2 , wherein the compound is 1-[11-(1-carboxycyclopropyl)-6-oxoundecyl]-1-cyclopropanecarboxylic acid, or a pharmaceutically acceptable salt thereof.
8. The method of claim 2 , wherein the compound is 1-[11-(1-carboxycyclopentyl)-6-oxoundecyl]-1-cyclopentanecarboxylic acid, or a pharmaceutically acceptable salt thereof.
9. The method of claim 1 , wherein the compound is selected from a group consisting of:
11-(1-carboxycyclopropyl)-2,2-dimethyl-7-oxoundecanoic acid;
11-(1-carboxycyclobutyl)-2,2-dimethyl-7-oxoundecanoic acid; and
13-(1-carboxycyclopropyl)-2,2-dimethyl-8-oxotridecanoic acid;
or a pharmaceutically acceptable salt thereof.
10. The method of claim 9 , wherein the compound is 11-(1-carboxycyclopropyl)-2,2-dimethyl-7-oxoundecanoic acid, or a pharmaceutically acceptable salt thereof.
11. The method of claim 9 , wherein the compound is 11-(1-carboxycyclobutyl)-2,2-dimethyl-7-oxoundecanoic acid, or a pharmaceutically acceptable salt thereof.
12. The method of claim 9 , wherein the compound is 13-(1-carboxycyclopropyl)-2,2-dimethyl-8-oxotridecanoic acid, or a pharmaceutically acceptable salt thereof.
13. The method of claim 1 , wherein the patient is in need of treatment for or prevention of insulin resistance.
14. The method of claim 1 , wherein the patient is in need of treatment for or prevention of a disorder of glucose metabolism.